The agreement concerns Crucell’s STAR technology which is useful for increasing production of recombinant antibodies and therapeutic proteins on mammalian cell lines. STAR technology supports high yield antibody and protein production. Using Crucell’s STAR technology, high levels of protein can be generated. This has been demonstrated in several CHO derivatives for numerous proteins and different antibodies.
Novo Nordisk intends to evaluate the STAR technology using its proprietary mammalian CHO cell line along with its antibodies.
Under the terms of the agreement, Novo Nordisk will pay a license issuance fee, a success-based fee and annual maintenance fees provided the license is extended upon evaluation. Financial details of the deal were not disclosed.